New Generation Vaccines for COVID-19 Based on Peptide, Viral Vector, Artificial  Antigen Presenting Cell, DNA or mRNA

Marzieh Rezaei; Mahboobeh  Nazari

doi:10.18502/ajmb.v14i1.8167

Marzieh Rezaei Department of Cell & Molecular Biology and Microbiology, Faculty of Science and Biotechnology, University of Isfahan, Isfahan, Iran
Mahboobeh Nazari Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran

DOI: https://doi.org/10.18502/ajmb.v14i1.8167

Keywords: COVID-19, Pandemics, SARS-CoV-2, Vaccines

Abstract

At present, effective vaccines have been developed as the most successful approaches for preventing widespread infectious disease. The global efforts are focusing with the aim of eliminating and overcoming the Coronavirus Disease 2019 (COVID-19) and are developing vaccines from the date it was announced as a pandemic disease. In this study, PubMed, Embase, Cochrane Library, Clinicaltrial.gov, WHO reports, Science Direct, Scopus, Google Scholar, and Springer databases were searched for finding the relevant studies about the COVID-19 vaccines. This article provides an overview of multiple vaccines that have been manufactured from December 2020 up to April 2021 and also offers a perspective on their efficacy, safety, advantages, and limitations. Currently, there are several categories of COVID-19 vaccines based on Protein Subunit (PS), Inactivated Virus (IV), Virus Like Particle (VLP), Live Attenuated Virus (LAV), Viral Vector (replicating) (VVr) and Viral Vector (non-replicating) (VVnr) in progress or finalized as indicated by the WHO reporting of April 1, 2020.